Table of Contents

Section I: TARGETTING AD

1. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings

Kaj Blennow and Henrik Zetterberg

2. Tracking down a missing trigger for Alzheimer's disease by mass spectrometric imaging based on brain network analysis

Minako Hoshi

3. Using mirror-image peptides to enhance robustness and reproducibility in studying the amyloid ß-protein

Ariel J. Kuhn and Jevgenij A. Raskatov

Section II: ETIOLOGY OF AD

4. In search of pathogenic amyloid ß-peptide in familial Alzheimer's disease

Michael S. Wolfe

5. Biology of splicing in Alzheimer's disease research

Kenichi Nagata, Takashi Saito, Takaomi C. Saido and Takashi Morihara

6. Acquired cerebral amyloid angiopathy: An emerging concept

Masahito Yamada, Tsuyoshi Hamaguchi and Kenji Sakai

Section III: NEUROIMMUNOLOGY OF AD

7. Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease

Goran Šimic, Ena Španic, Lea Langer Horvat and Patrick R. Hof

8. Gut microbiota mediated allostasis prevents stress-induced neuroinflammatory risk factors of Alzheimer's disease

Susan Westfall, Umar Iqbal, Maria Sebastian and Giulio Maria Pasinetti

9. Neuroimmune interactions in Alzheimer’s disease—New frontier with old challenges?

Stefan Prokop, Virginia M.Y. Lee and John Q. Trojanowski

Section IV: AD THERAPY

10. Alzheimer's therapy development: A few points to consider

Einar M. Sigurdsson

11. The next steps in curing Alzheimer's disease

Fred W. van Leeuwen

12. Future horizons in Alzheimer's disease research

Thomas Wisniewski and Eleanor Drummond

13. Why delay in effective treatment for Alzheimer's disease and related conditions

Khalid Iqbal, Fei Liu, ChengXin Gong, Chunling Dai and Wen Hu

14. Restoring synaptic function through multimodal therapeutics

Raul Loera-Valencia, Muhammad-Al-Mustafa Ismail, Per Nilsson and Bengt Winblad

15. Disease-modifying therapy for proteinopathies: Can the exception become the rule?

Gal Bitan

16. Combination therapy for Alzheimer’s disease and related dementias

Martin M. Bednar

Section V: ALPHA-SYNUCLEINOPATHIES

17. Can infections trigger alpha-synucleinopathies?

Christopher T. Tulisiak, Gabriela Mercado, Wouter Peelaerts, Lena Brundin and Patrik Brundin

18. Prion-like propagation of a-synuclein in neurodegenerative diseases

Airi Tarutani and Masato Hasegawa

Section VI: MODEL SYSTEMS

19. Yeast models of neurodegenerative diseases

Mick F. Tuite

About the Author

David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid ß-protein (Alzheimer's disease) and a-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Co-Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.